Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.
Study Type
OBSERVATIONAL
Enrollment
476
All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
Montefiore Health System
The Bronx, New York, United States
ATTR-CM Diagnosis
The number of patients who underwent a PYP SPECT scan diagnostic of ATTR-CM will be assessed and reported
Time frame: During the index PYP scan within the study time frame parameters of the retrospective review (between 2014 and 2023)
Mortality
The number of patients who died from all-cause mortality will be tabulated and reported
Time frame: Within the study time frame parameters of the retrospective review (between 2014 and 2023)
Heart failure hospitalizations
The number of patients admitted to the hospital with a primary diagnosis of heart failure will be tabulated and reported
Time frame: Within the study time frame parameters of the retrospective review (between 2014 and 2023)
Total Hospitalizations
The number of patients admitted to the hospital with any diagnosis will be tabulated and reported
Time frame: Within the study time frame parameters of the retrospective review (between 2014 and 2023)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.